This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aflibercept, Vascular Endothelial Growth Factor Trap (VEGF Trap - Oncological), AVE0005, ziv-aflibercept
Due to partnership considerations, BioMedTracker has separate drug profiles for the ocular and oncological indications of aflibercept (VEGF Trap). Please also see Eylea.
Afilbercept is a fusion protein designed to bind both VEGF-A and VEGF-B. VEGF contributes to the formation of new blood vessels including new blood vessels supplying nutrients to developing tumors.
In preclinical studies, the afilbercept also binds to another vascular growth factor, Placental Growth Factor (PLGF) which also may play a role in blood supply to tumors.
Aventis and Regeneron Pharmaceuticals entered into a global (excluding Japan) agreement in September 2003 under which the companies will jointly develop and commercialize VEGF Trap, Regeneron's lead anti-angiogenesis compound.
Under the terms of the agreement, Aventis will pay Regeneron $125 million, of which $45 million is an investment in newly issued Regeneron common stock and $80 million is an upfront payment. Anadditional payment of $25 million is linked to an early clinical milestone. The two companies will share equally promotion rights and profits globally. Aventis will also pay Regeneron up to $360 million at identified milestones related to the receipt of marketing approvals for up to eight indications in Europe and the United States. Aventis will also fund development costs. The companies will jointly develop VEGF Trap in oncology, ophthalmology, and possibly in otherindications. Should the collaboration become profitable, Regeneron will pay back to Aventis 50% of...See full deal structure in Biomedtracker
Partners: Regeneron Pharmaceuticals, Inc.
Additional information available to subscribers only: